These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 15171510)

  • 1. [Diabetes update: preventing type 2 diabetes. Individualized stepwise therapy (oral antidiabetic agents). Multifactorial intervention].
    Müller B; Trepp R
    Praxis (Bern 1994); 2004 Apr; 93(18):753-62. PubMed ID: 15171510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired glucose tolerance and impaired fasting glucose--a review of diagnosis, clinical implications and management.
    Petersen JL; McGuire DK
    Diab Vasc Dis Res; 2005 Feb; 2(1):9-15. PubMed ID: 16305067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [In high risk for diabetes should drugs be used for prevention? (interview by Dr. Judith Neumaier)].
    Hanefeld M
    MMW Fortschr Med; 2002 Oct; 144(40):12. PubMed ID: 12440285
    [No Abstract]   [Full Text] [Related]  

  • 4. [Diabetes prevention program (metformin)].
    Kusaka I; Nagasaka S
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():471-7. PubMed ID: 15779424
    [No Abstract]   [Full Text] [Related]  

  • 5. Treating non-insulin-dependent diabetes. Oral agents or insulin?
    Shlossberg AH
    Can Fam Physician; 1993 Jan; 39():119-20, 123-6. PubMed ID: 8435549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preventing type 2 diabetes using combination therapy: design and methods of the CAnadian Normoglycaemia Outcomes Evaluation (CANOE) trial.
    Zinman B; Harris SB; Gerstein HC; Young TK; Raboud JM; Neuman J; Hanley AJ
    Diabetes Obes Metab; 2006 Sep; 8(5):531-7. PubMed ID: 16918588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetes: update on management and therapy.
    Reed JW
    Ethn Dis; 2002; 12(1):S2-20-2. PubMed ID: 11913632
    [No Abstract]   [Full Text] [Related]  

  • 8. Insulin resistance, beta cell function and cardiovascular risk factors in Ghanaians with varying degrees of glucose tolerance.
    Amoah AG; Schuster DP; Gaillard T; Osei K
    Ethn Dis; 2002; 12(4):S3-10-7. PubMed ID: 12477148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promising new approaches.
    Reasner CA
    Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a multifactorial intervention on mortality in type 2 diabetes.
    Gaede P; Lund-Andersen H; Parving HH; Pedersen O
    N Engl J Med; 2008 Feb; 358(6):580-91. PubMed ID: 18256393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular manifestations of insulin resistance.
    Chahwala V; Arora R
    Am J Ther; 2009; 16(5):e14-28. PubMed ID: 19114874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Differences between diabetes mellitus type 2 patients switched and not switched over to insulin treatment after specialist consultation].
    Goddijn PP; Meyboom-de Jong B; Feskens EJ; van Ballegooie E; Bilo HJ
    Ned Tijdschr Geneeskd; 1998 May; 142(18):1023-6. PubMed ID: 9623204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing antidiabetic treatment options for patients with type 2 diabetes mellitus and cardiovascular comorbidities.
    Malesker MA
    Pharmacotherapy; 2008 Feb; 28(2):193-206. PubMed ID: 18225965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Could oral antidiabetic agents be useful in the management of different types of diabetes and syndromes of insulin resistance in children and adolescents?].
    Otto-Buczkowska E; Nowowiejska B; Jarosz-Chobot P; Stańczyk J
    Przegl Lek; 2009; 66(7):388-93. PubMed ID: 20043582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes.
    Kadoglou NP; Kapelouzou A; Tsanikidis H; Vitta I; Liapis CD; Sailer N
    Exp Clin Endocrinol Diabetes; 2011 Feb; 119(2):63-8. PubMed ID: 21031343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of metabolic syndrome.
    Wagh A; Stone NJ
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):213-28. PubMed ID: 15151470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of lifestyle and oral anti-diabetic agents to prevent type 2 diabetes mellitus and cardiovascular disease.
    Bethel MA; Califf RM
    Am J Cardiol; 2007 Mar; 99(5):726-31. PubMed ID: 17317381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Primary combined oral antidiabetic therapy in type-2 diabetes mellitus].
    Winkler G; Baranyi E
    Orv Hetil; 2002 Oct; 143(43):2441-7. PubMed ID: 12455146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Differential type 2 diabetes therapy based on pathophysiological aspects].
    Hanefeld M; Fischer S
    Ther Umsch; 2002 Aug; 59(8):393-401. PubMed ID: 12235731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.